sk&f 86002 has been researched along with Kaposi Sarcoma in 2 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bender Ignacio, RA | 1 |
Lee, JY | 1 |
Rudek, MA | 1 |
Dittmer, DP | 1 |
Ambinder, RF | 1 |
Krown, SE | 1 |
Sodhi, A | 1 |
Montaner, S | 1 |
Patel, V | 1 |
Zohar, M | 1 |
Bais, C | 1 |
Mesri, EA | 1 |
Gutkind, JS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma[NCT00686842] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Drug supply unavailable.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Patients who experienced an adverse event of grade 3 or greater (NCT00686842)
Timeframe: All study visits
Intervention | participants (Number) |
---|---|
VEGF Inhibitor PTC299 | 7 |
1 trial available for sk&f 86002 and Kaposi Sarcoma
Article | Year |
---|---|
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; DNA, Viral; Enzyme | 2016 |
1 other study available for sk&f 86002 and Kaposi Sarcoma
Article | Year |
---|---|
The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha.
Topics: 3T3 Cells; Animals; Calcium-Calmodulin-Dependent Protein Kinases; COS Cells; DNA-Binding Proteins; E | 2000 |